Tarik Haddad

446 total citations
10 papers, 308 citations indexed

About

Tarik Haddad is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Rheumatology. According to data from OpenAlex, Tarik Haddad has authored 10 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 3 papers in Surgery and 2 papers in Rheumatology. Recurrent topics in Tarik Haddad's work include Transplantation: Methods and Outcomes (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Eosinophilic Disorders and Syndromes (2 papers). Tarik Haddad is often cited by papers focused on Transplantation: Methods and Outcomes (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Eosinophilic Disorders and Syndromes (2 papers). Tarik Haddad collaborates with scholars based in United States, Australia and Belgium. Tarik Haddad's co-authors include Lisa Lancaster, Ian Glaspole, Chris Kell, Joseph M. Parker, Stephanie L. Roseti, Ethan Grant, Dewei She, Kevin R. Flaherty, Fernando J. Martínez and M. Mack and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and Critical Care Medicine.

In The Last Decade

Tarik Haddad

9 papers receiving 303 citations

Peers

Tarik Haddad

PRM

SURGE

PHYSI

IMMUN

MB

Hirotaka Nishikiori Japan

Sho Shibata Japan

Annalisa Fui Italy

Rimlee Dutta India

Georg Mynarek Norway

Naoko Katsurada Japan

Lauren T. Crum United States

Yohei Yatagai Japan

Carlos González-Juanatey Spain

Tetsujiro Fukami Japan

Hirotaka Nishikiori Japan

Tarik Haddad

311 ×1.4

PRM

41 ×0.9

SURGE

83 ×2.2

PHYSI

37 ×1.0

IMMUN

35 ×1.0

MB

Citations per year, relative to Tarik Haddad Tarik Haddad (= 1×) peers Hirotaka Nishikiori

Countries citing papers authored by Tarik Haddad

Since Specialization

Citations

This map shows the geographic impact of Tarik Haddad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarik Haddad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarik Haddad more than expected).

Fields of papers citing papers by Tarik Haddad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tarik Haddad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarik Haddad. The network helps show where Tarik Haddad may publish in the future.

Co-authorship network of co-authors of Tarik Haddad

This figure shows the co-authorship network connecting the top 25 collaborators of Tarik Haddad. A scholar is included among the top collaborators of Tarik Haddad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarik Haddad. Tarik Haddad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Haddad, Tarik, et al.. (2025). Ionized Hypocalcemia and ICU Mortality: Marker of Severity or Modifiable Risk Factor?. Critical Care Medicine. 53(11). e2380–e2381.

2.

Parker, Joseph M., Ian Glaspole, Lisa Lancaster, et al.. (2017). A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 197(1). 94–103. 90 indexed citations

3.

Taylor‐Cousar, Jennifer L., Manu Jain, Tarik Haddad, et al.. (2017). Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. Journal of Cystic Fibrosis. 17(2). 228–235. 56 indexed citations

4.

Raghu, Ganesh, Fernando J. Martínez, Kevin K. Brown, et al.. (2015). CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. European Respiratory Journal. 46(6). 1740–1750. 101 indexed citations

5.

Haddad, Tarik, et al.. (2013). Management of Scedosporium apiospermum in a pre- and post-lung transplant patient with cystic fibrosis. Medical Mycology Case Reports. 2. 37–39. 16 indexed citations

6.

Caldeira, Christiano, et al.. (2013). Reconstruction of pulmonary venous conduit with CorMatrix in lung transplant. Asian Cardiovascular and Thoracic Annals. 21(3). 360–362. 4 indexed citations

7.

Weston, Mark, Mark W. Rolfe, Tarik Haddad, & Mayra Lopez‐Cepero. (2009). Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.. PubMed. 393–9. 16 indexed citations

8.

Ferguson, Robert P., et al.. (2008). Survival After In-Hospital Cardiopulmonary Resuscitation. Southern Medical Journal. 101(10). 1007–1011. 13 indexed citations

9.

Haddad, Tarik, et al.. (2007). Emerging drugs in lung transplantation. Expert Opinion on Emerging Drugs. 12(1). 61–73. 4 indexed citations

10.

Haddad, Tarik, William Lunn, Sivagini Ganesh, et al.. (2007). VANISHING BRONCHUS SYNDROME. CHEST Journal. 132(4). 595B–595B. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact